Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ocular Therapeut (OCUL)

Ocular Therapeut (OCUL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,951,511
  • Shares Outstanding, K 213,047
  • Annual Sales, $ 63,720 K
  • Annual Income, $ -193,510 K
  • EBIT $ -251 M
  • EBITDA $ -247 M
  • 60-Month Beta 0.90
  • Price/Sales 36.54
  • Price/Cash Flow N/A
  • Price/Book 6.00

Options Overview Details

View History
  • Implied Volatility 320.40% (-12.58%)
  • Historical Volatility 55.23%
  • IV Percentile 98%
  • IV Rank 87.80%
  • IV High 358.54% on 02/03/26
  • IV Low 46.01% on 08/22/25
  • Expected Move (DTE 13) 2.47 (26.91%)
  • Put/Call Vol Ratio 0.69
  • Today's Volume 11,341
  • Volume Avg (30-Day) 13,278
  • Put/Call OI Ratio 0.98
  • Today's Open Interest 191,702
  • Open Int (30-Day) 141,651
  • Expected Range 6.70 to 11.63

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.33
  • Number of Estimates 5
  • High Estimate -0.32
  • Low Estimate -0.34
  • Prior Year -0.37
  • Growth Rate Est. (year over year) +10.81%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.35 +9.63%
on 02/03/26
13.03 -29.70%
on 01/15/26
-2.09 (-18.58%)
since 01/06/26
3-Month
8.35 +9.63%
on 02/03/26
16.44 -44.28%
on 12/08/25
-1.47 (-13.83%)
since 11/06/25
52-Week
5.78 +58.34%
on 03/04/25
16.44 -44.28%
on 12/08/25
+1.52 (+19.90%)
since 02/06/25

Most Recent Stories

More News
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced...

OCUL : 9.16 (+2.81%)
Ocular Therapeutix (NASDAQ:OCUL) Misses Q4 CY2025 Revenue Estimates

Ocular Therapeutix (NASDAQ:OCUL) Misses Q4 CY2025 Revenue Estimates

OCUL : 9.16 (+2.81%)
Ocular Therapeutix: Q4 Earnings Snapshot

Ocular Therapeutix: Q4 Earnings Snapshot

OCUL : 9.16 (+2.81%)
Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

SOL-1 Phase 3 superiority trial results remain masked to date SOL-1 data expected to be presented at the 49 th Macula Society Annual Meeting Ocular plans to submit NDA for AXPAXLI™...

OCUL : 9.16 (+2.81%)
A Look Back at Pharmaceuticals Stocks’ Q3 Earnings: Ocular Therapeutix (NASDAQ:OCUL) Vs The Rest Of The Pack

A Look Back at Pharmaceuticals Stocks’ Q3 Earnings: Ocular Therapeutix (NASDAQ:OCUL) Vs The Rest Of The Pack

OCUL : 9.16 (+2.81%)
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced...

OCUL : 9.16 (+2.81%)
Ocular Therapeutix™ Appoints David W. Robinson as Global Chief Commercial Officer

Accomplished global commercial leader with deep expertise in retina drug launches Primary architect for the industry-defining launch of EYLEA ® while at Regeneron Most recently served as...

OCUL : 9.16 (+2.81%)
3 Cash-Burning Stocks We’re Skeptical Of

3 Cash-Burning Stocks We’re Skeptical Of

RKLB : 72.32 (+9.05%)
NMRK : 16.85 (+4.14%)
OCUL : 9.16 (+2.81%)
1 Healthcare Stock to Consider Right Now and 2 We Find Risky

1 Healthcare Stock to Consider Right Now and 2 We Find Risky

TXG : 18.61 (+5.14%)
ABT : 110.83 (+1.60%)
OCUL : 9.16 (+2.81%)
3 Reasons OCUL is Risky and 1 Stock to Buy Instead

3 Reasons OCUL is Risky and 1 Stock to Buy Instead

OCUL : 9.16 (+2.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular...

See More

Key Turning Points

3rd Resistance Point 9.65
2nd Resistance Point 9.47
1st Resistance Point 9.31
Last Price 9.16
1st Support Level 8.98
2nd Support Level 8.80
3rd Support Level 8.64

See More

52-Week High 16.44
Fibonacci 61.8% 12.37
Fibonacci 50% 11.11
Fibonacci 38.2% 9.86
Last Price 9.16
52-Week Low 5.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar